PRQR vs TNXP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe fundamental weakness across all measured financial dimensions. While the company maintains a strong liquidity position with a Current Ratio of 3.09 and low Debt/Equity (0.32), it suffers from extreme operational inefficiency with a profit margin of -258.05%. There is a stark divergence between the objective financial data and the 'Strong Buy' analyst consensus, suggesting the valuation is based on speculative pipeline catalysts rather than current fiscal performance. The technical trend is entirely bearish (0/100), further compounding the negative outlook.
TNXP exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -895.84%. While the company maintains a high current ratio (7.42) and low debt, these are likely the result of aggressive equity dilution rather than operational success, as evidenced by a -100% 5-year price return. Despite a 'strong_buy' analyst consensus and high revenue growth, the lack of earnings beats (0/4 in the last year) and a total collapse in long-term shareholder value indicate a high-risk profile. The disconnect between the analyst target price ($54.33) and the fundamental decay is extreme.
Compare Another Pair
Related Comparisons
PRQR vs TNXP: Head-to-Head Comparison
This page compares ProQR Therapeutics N.V. (PRQR) and Tonix Pharmaceuticals Holding Corp. (TNXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.